上海辰光医疗科技股份有限公司 证券代码：920300 证券简称：辰光医疗 公告编号：2026-008 关于注销部分募集资金专项账户的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 | 序 | 账户名称 | 银行名称 | 账号 | 募集资金专 | 账户状态 | | --- | --- | --- | --- | --- | --- | | 号 | | | | 户用途 | | | 1 | 上 海 辰 光 医 疗 科 技 | 中国建设银行股 份有限公司上海 | | 磁共振系统 集成研发产 | 正常使用 | | | 股 份 有 限 | 长三角一体化示 | 31050183360009998888 | 业化及营销 | | | | 公司 | 范区支行 | | 升级项目 | | | 2 | 上 海 辰 光 医 疗 科 技 | 招商银行股份有 限公司上海青浦 | 121914073010818 | 科研定制型 超导磁体研 | 本次注销 | | | 股 份 有 限 | | | | | | | 公司 | 支行 | | ...

| 1.基本情况 | | | | | | --- | --- | --- | --- | --- | | 信息披露义务人 | 田丽芬 | | | | | 持股变动时间 | 2025 年 11 月 13 日-2026 年 1 月 9 日 | | | | | 股票简称 | 辰光医疗 | 股票代码 | 920300 | | | 变动类型 | 增加□ 减少√ | 是否存在一致 | 是√ | 否□ | | | | 行动人 | | | 证券代码：920300 证券简称：辰光医疗 公告编号：2026-007 上海辰光医疗科技股份有限公司 合计持股 5%以上股东权益变动达到 1%的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 股东田丽芬与股东上海复孵科技有限公司的控股股东、实际控制人侯晓远系 夫妻关系，互为一致行动人,本次股份减持前，上述一致行动人合计拥有权益的 股份占上海辰光医疗科技股份有限公司（以下简称"公司"）已发行股份的比例 为 8.1823%。 公司于 2026 年 1 月 9 日收到股东田丽芬 ...

国泰海通证券股份有限公司 关于上海辰光医疗科技股份有限公司 使用闲置募集资金进行现金管理的核查意见 二、募集资金使用情况 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海辰光医疗科技股份有限公司（以下简称"辰光医疗"或"公司"）向不特定 合格投资者公开发行股票并在北交所上市持续督导的保荐机构，根据《证券发行 上市保荐业务管理办法》《北京证券交易所股票上市规则》《北京证券交易所证券 发行上市保荐业务管理细则》等相关法律、法规和规范性文件的规定，对公司使 用闲置募集资金进行现金管理进行了核查，核查情况与意见如下： 一、募集资金基本情况 辰光医疗经中国证券监督管理委员会《关于核准上海辰光医疗科技股份有限 公司向不特定合格投资者公开发行股票的批复》（证监许可[2022]2882号）核准， 向不特定合格投资者公开发行人民币普通股1,500.00万股，发行价为每股人民币 6.00元，共计募集资金总额为人民币90,000,000.00元，实际募集资金净额为 72,621,981.14元。上述募集资金到位情况经中汇会计师事务所（特殊普通合伙） 审验，并由其于2022年11月30日出具了《验资报告》（中 ...

证券代码：920300 证券简称：辰光医疗 公告编号：2026-005 上海辰光医疗科技股份有限公司 关于公司使用闲置募集资金进行现金管理公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、募集资金基本情况 2022 年 12 月 7 日，上海辰光医疗科技股份有限公司发行普通股 15,000,000 股，发行方式为向不特定合格投资者公开发行，发行价格为 6.00 元/股，募集资 金总额为 90,000,000.00 元，实际募集资金净额为 72,621,981.14 元，到账时间 为 2022 年 11 月 30 日。 公司行使超额配售选择权取得的募集资金净额为 12,149,787.74 元，到账时 间为 2023 年 1 月 9 日。上述募集资金到位情况已经中汇会计师事务所（特殊普 通合伙）验证，并出具中汇会验[2022]7703 号《验资报告》和中汇会验[2023]0024 号《验资报告》。 二、募集资金使用情况 （一）募集资金使用情况和存储情况 截至 2025 年 12 月 31 日，公司 ...

证券代码：920300 证券简称：辰光医疗 公告编号：2026-004 上海辰光医疗科技股份有限公司 第五届董事会第二十六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2026 年 1 月 10 日 2.会议召开地点：上海市青浦区华青路 1269 号 3.会议召开方式：现场会议 4.发出董事会会议通知的时间和方式：2026 年 1 月 5 日以书面、电话和微信 方式发出 5.会议主持人：董事长 王杰 先生 6.会议列席人员：高级管理人员 1.议案内容： 为进一步提高公司资金的使用效率和收益，公司拟使用不超过 1,000 万元 的闲置募集资金在中国建设银行股份有限公司上海长三角一体化示范区支行 7.召开情况合法合规的说明： 会议的召集、召开和表决程序符合有关法律、行政法规、规范性文件和《公 司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《关于公司使用 ...

Group 1 - The report highlights the launch of "ChatGPT Health" by OpenAI, which integrates health-related conversations and connects to electronic medical records, indicating a significant potential market for AI in healthcare [9][12] - The "Artificial Intelligence + Manufacturing" initiative aims to achieve reliable supply of core AI technologies and maintain a leading position in the industry by 2027, with specific targets including the application of 3-5 general large models in manufacturing and the creation of 100 high-quality industrial datasets [12][14] - The report identifies key sectors such as AI healthcare, AI pharmaceuticals, and AI biomanufacturing as focal points for development, proposing measures like building intelligent drug discovery platforms and smart supply chain management systems [16][12] Group 2 - The North Exchange's biopharmaceutical sector saw a weekly increase of 5.85%, with medical devices rising by 7.81%, indicating strong market performance [23][26] - Among the biopharmaceutical companies, 90.48% experienced stock price increases, with notable performers including BeiYikang (+45.1%) and XinGanjian (+10.46%) [33][34] - As of January 9, 2026, there are 15 companies in the biopharmaceutical sector awaiting approval on the North Exchange, with an average projected revenue of 424 million yuan for 2024 [34][38] Group 3 - The report emphasizes the importance of AI in enhancing drug development efficiency and supply chain management, aiming to reduce costs and time in pharmaceutical processes [16][12] - The global AI healthcare market is projected to reach approximately $26.65 billion in 2024, with a compound annual growth rate (CAGR) of 38.8% expected until 2033 [18][17] - The Chinese AI healthcare industry is expected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting significant growth potential in this sector [18][19]

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

Summary of Key Points Core Viewpoint The trading volume and value of stocks on the Beijing Stock Exchange (BSE) saw significant increases on January 6, with a total trading volume of 1.007 billion shares and a trading value of 26.037 billion yuan, marking an increase of 4.849 billion yuan compared to the previous trading day. The majority of stocks experienced price increases, indicating a positive market sentiment. Trading Performance - Total trading volume reached 1.007 billion shares, with a trading value of 26.037 billion yuan, an increase of 4.849 billion yuan from the previous day [1]. - Out of the tradable stocks, 264 stocks closed higher, accounting for 92.31% of the total, while only 21 stocks closed lower [1]. - Notable gainers included Guoyuan Technology, Haixi Communications, and Dapeng Industrial, with increases of 24.30%, 16.85%, and 15.90% respectively [1]. - The stocks with the highest trading value included Hengtong Technology, Tianli Composite, and Nacono, with trading values of 1.387 billion yuan, 1.107 billion yuan, and 628.275 million yuan respectively [1]. Stock Activity - A total of 68 stocks had trading volumes exceeding 100 million yuan, indicating high trading activity [1]. - The turnover rate for stocks was notably high, with 31 stocks having turnover rates exceeding 10%, and 6 stocks exceeding 20% [1]. - The stocks with the highest turnover rates included Dapeng Industrial, Jinhao Medical, and Hanxin Technology, with rates of 42.72%, 32.55%, and 25.42% respectively [1].

Group 1 - The core point of the article is that Chen Guang Medical (920300) experienced a significant increase of 12.56% in its stock price, with a trading volume of 2.75 billion yuan and a turnover rate of 24.13% on the day [1][2] - Institutional investors net bought 3.53 million yuan, while brokerage seats collectively net sold 12.28 million yuan [1][2] - The stock was listed on the exchange due to its high turnover rate, with the top five brokerage seats contributing a total transaction volume of 63.01 million yuan, where the buying amount was 27.13 million yuan and the selling amount was 35.88 million yuan, resulting in a net sell of 8.75 million yuan [2] Group 2 - The top buying brokerage seat was an institutional specialized seat, which bought 6.28 million yuan and sold 2.75 million yuan, resulting in a net purchase of 3.53 million yuan [2] - The second largest buying seat was Dongfang Securities, which bought 6.15 million yuan without any selling [2] - The selling activities were led by CITIC Securities, which sold 5.45 million yuan while buying only 0.52 million yuan [2]

证券代码：920300 证券简称：辰光医疗 公告编号：2026-003 上海辰光医疗科技股份有限公司 关于召开 2026 年第一次临时股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本次股东会的召集、召开符合《公司法》有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 （四）会议召开方式 一、会议召开基本情况 （一）股东会届次 本次会议为 2026 年第一次临时股东会。 （二）召集人 本次股东会的召集人为董事会。 上海辰光医疗科技股份有限公司（以下简称"公司"）于 2026 年 1 月 3 日 召开第五届董事会第二十五次会议，审议通过了《关于召开 2026 年第一次临时 股东会通知的议案》。 （三）会议召开的合法合规性 本次会议采用现场投票和网络投票相结合方式召开。 公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现 重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2026 年 1 月 20 日下午 ...